SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

ABCL386

ABCL·AbCellera Biologics Inc.
NEUTRAL
Drug Impact Rating0/10
Trial phase
Unknown / Not publicly disclosed
Time to market
Not estimable; the drug candidate has no public presence.
Why 0/10
No hard, dated catalyst exists for ABCL386 because the drug could not be identified in any public source. Impact score is 0 as there is no evidence this is a real, disclosed program.
Actionable Insight NEUTRAL

No actionable catalyst exists for ABCL386 because the drug candidate could not be identified in any public source. Investors should verify the correct drug code; AbCellera's next major catalyst is the advancement of ABCL635 into Phase 3 development, which the company guided for 2027 after positive Phase 2 data reported in August 2026.

Price Chart

Loading chart...

Executive Summary

Extensive research across web searches, news databases, SEC filings, ClinicalTrials.gov, FDA records, and internal SecBot databases found zero mentions of a drug candidate called "ABCL386" from AbCellera Biologics or any other developer. AbCellera Biologics (NASDAQ: ABCL) is a real antibody discovery and development company, but its known proprietary pipeline consists of ABCL635 (Phase 2, menopausal hot flashes) and ABCL575 (Phase 1, atopic dermatitis). No evidence exists that ABCL386 is or was a publicly disclosed program.

How It Works

Not determinable from public sources. ABCL386 could not be identified as a disclosed drug candidate.

Trial Status

No clinical trials, regulatory filings, or press releases referencing ABCL386 were found in any public database.

The Two-Sided Case

▲ Bull Case1
No bull case can be constructed because ABCL386 does not appear in any public source as a real drug candidate from AbCellera Biologics.
▼ Bear Case2
The drug code ABCL386 could not be found in any SEC filing, clinical trial registry, press release, news article, or analyst report, suggesting it may be a typo, an internal code that was never publicly disclosed, or a candidate that was discontinued before public announcement.
AbCellera's known proprietary pipeline consists only of ABCL635 (Phase 2, hot flashes) and ABCL575 (Phase 1, atopic dermatitis); no third proprietary candidate has been publicly named.

Upcoming Catalysts

  • None identified for ABCL386. For AbCellera broadly: Phase 3 initiation for ABCL635 guided for 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbCellera Biologics Inc. 8-K ABCL ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 businesswire.com3 seekingalpha.com